Prosetin in Healthy Volunteers and Participants With ALS

Phase 1, randomised, double-blind trial of prosetin in amyotrophic lateral sclerosis (ALS) (7 arms), sponsored by ProJenX. Primary endpoints: Number of Participants Experiencing Adverse Events and Serious Adverse Events at 54 weeks, Number of Participants with Clinically Significant Laboratory Test Abnormalities at 54 weeks and 6 more. Started Feb 2022; status: active, not recruiting.